Arcturus Therapeutics Holdings Inc.

# Arcturus Therapeutics Holdings Inc.

Based in San Diego, California, Arcturus Therapeutics is a publicly traded biotechnology company developing mRNA-based therapeutics and vaccines targeting infectious diseases and rare genetic conditions. The company operates two proprietary technology platforms: LUNAR, a lipid-mediated delivery system for mRNA therapeutics, and STARR, an mRNA platform technology. These platforms serve as the foundation for its clinical-stage pipeline across multiple therapeutic areas.

The company's development programs span infectious disease vaccines and treatments for liver and respiratory rare diseases. Lead candidates include ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis, both in Phase 2 clinical trials. The infectious disease pipeline encompasses seasonal influenza, pandemic influenza H5N1, and COVID-19 vaccine candidates at various stages of development, with ARCT-2301 and ARCT-2303 advancing to Phase 3 clinical trials for COVID-19 applications.

Arcturus operates as a development-stage company with 174 full-time employees. The company was incorporated in Delaware and incorporated in 2013, with its primary operations and headquarters located in San Diego. As a clinical-stage biopharmaceutical firm, the company has not yet generated significant product-based revenue streams.